Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection)
2005年5月25日 - 10:30AM
PRニュース・ワイアー (英語)
Eyetech Announces Conference Call to Reiterate Confidence in
Macugen(R) (Pegaptanib Sodium Injection) NEW YORK, May 24
/PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc.
(NASDAQ:EYET) announced that it will hold a conference call to
reiterate its confidence in Macugen and discuss issues presented by
a potential competitor's recently released preliminary, top-line
clinical trial data for the potential use of an antibody fragment
in the treatment of neovascular age-related macular degeneration
(neovascular AMD). Neovascular AMD is the leading cause of
blindness in people over 60 years of age. (Logo:
http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO ) Conference
Call and Webcast Information Eyetech will hold the conference call
and simultaneous webcast on Thursday, May 26, 2005, at 8:30 a.m.,
Eastern Time. Live audio of the conference call will be available
to investors, members of the news media and the general public by
dialing 888-275-0218 (in the United States) or 706-679-7756
(internationally). A playback of the call will be available through
June 1, 2005 by dialing 800-642-1687, passcode 6644652 (in the
United States), or 706-645-9291, passcode 6644652
(internationally). To access the call by live webcast, please log
on to the Investor Relations section of Eyetech's website at
http://www.eyetech.com/ . An archived version of the webcast will
be available at the same location through June 1, 2005. About
Macugen Macugen is indicated in the United States and Brazil for
the treatment of neovascular age-related macular degeneration and
in Canada for subfoveal choroidal neovascularization (CNV)
secondary to neovascular AMD. Macugen is a pegylated anti-VEGF
aptamer, which binds to vascular endothelial growth factor (VEGF).
VEGF is a protein that plays a critical role in angiogenesis (the
formation of new blood vessels) and increased permeability (leakage
from blood vessels), two of the pathological processes that
contribute to the vision loss associated with neovascular AMD. For
full prescribing information about Macugen, please visit
http://www.macugen.com/ . About Eyetech Pharmaceuticals, Inc.
Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that
specializes in the development and commercialization of novel
therapeutics to treat diseases of the eye. Eyetech's initial focus
is on diseases affecting the back of the eye. Eyetech is
commercializing and further developing Macugen(R) (pegaptanib
sodium injection) with Pfizer Inc for the treatment of neovascular
AMD. Macugen is also being studied for other indications including
diabetic macular edema and retinal vein occlusion.
http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGODATASOURCE:
Eyetech Pharmaceuticals, Inc. CONTACT: Media: Chris Smith, Public
Relations & Corporate Communications, Eyetech Pharmaceuticals,
Inc., +1-212-824-3203, Mobile: +1-973-489-5076, , Investors: Glenn
Sblendorio Chief Financial Officer, Eyetech Pharmaceuticals, Inc.,
+1-212-824-3121, Web site: http://www.eyetech.com/
http://www.macugen.com/
Copyright
Eyetech (NASDAQ:EYET)
過去 株価チャート
から 5 2024 まで 6 2024
Eyetech (NASDAQ:EYET)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Eyetech Pharmaceuticals (MM) (ナスダック市場): 0 recent articles
その他のEyetech Pharmaceuticals (MM)ニュース記事